VTv Therapeutics Inc. unit vTv Therapeutics LLC entered licensing agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. and Reneo Pharmaceuticals Inc.
Huadong secured exclusive and sublicensable rights to develop and commercialize vTv's glucagon-like peptide-1 receptor agonist program for the treatment of type 2 diabetes, including the compound TTP273, in China and certain other pacific rim countries, including Australia and South Korea.
The Chinese pharmaceutical company will pay an initial license fee of $8.0 million, up to $25.0 million in potential development and regulatory milestone payments, an additional $20.0 million in milestone payment if Hangzhou receives regulatory approval for a central nervous system indication and $50.0 million in potential sales-based milestones, as well as tiered royalty payments ranging from low-single to low-double digit rates.
VTv's subsidiary will also pay up to $3.0 million for a phase 2 clinical trial of TTP273 in patients with type 2 diabetes.
Meanwhile, Reneo secured exclusive sublicensable global rights to develop and commercialize vTv's program to prevent muscle weakness associated with PMV and critical injury.
As part of the deal, Reneo will pay the vTv unit an initial license fee of $3.0 million, potential development, regulatory and sales-based milestone payments up to $94.5 million and tiered royalty payments at mid-single- to low double-digit rates.
In addition, vTv received an ownership interest in Reneo's common stock.